- Home
- NINE vs CVKD Comparison
NINE vs CVKD Comparison
Compare NINE & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NINE
- CVKD
- Stock Information
- Founded
- NINE 2011
- CVKD 2022
- Country
- NINE United States
- CVKD United States
- Employees
- NINE N/A
- CVKD N/A
- Industry
- NINE Oilfield Services/Equipment
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- NINE Energy
- CVKD Health Care
- Exchange
- NINE Nasdaq
- CVKD Nasdaq
- Market Cap
- NINE 27.5M
- CVKD 27.0M
- IPO Year
- NINE 2018
- CVKD 2023
- Fundamental
- Price
- NINE $0.58
- CVKD $12.84
- Analyst Decision
- NINE
- CVKD Strong Buy
- Analyst Count
- NINE 0
- CVKD 1
- Target Price
- NINE N/A
- CVKD $32.00
- AVG Volume (30 Days)
- NINE 737.2K
- CVKD 28.0K
- Earning Date
- NINE 10-30-2025
- CVKD 11-06-2025
- Dividend Yield
- NINE N/A
- CVKD N/A
- EPS Growth
- NINE N/A
- CVKD N/A
- EPS
- NINE N/A
- CVKD N/A
- Revenue
- NINE $577,300,000.00
- CVKD N/A
- Revenue This Year
- NINE $4.56
- CVKD N/A
- Revenue Next Year
- NINE $1.41
- CVKD N/A
- P/E Ratio
- NINE N/A
- CVKD N/A
- Revenue Growth
- NINE 3.23
- CVKD N/A
- 52 Week Low
- NINE $0.44
- CVKD $8.74
- 52 Week High
- NINE $1.87
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- NINE 41.31
- CVKD 41.79
- Support Level
- NINE $0.53
- CVKD $13.51
- Resistance Level
- NINE $0.64
- CVKD $14.35
- Average True Range (ATR)
- NINE 0.05
- CVKD 0.52
- MACD
- NINE -0.01
- CVKD -0.13
- Stochastic Oscillator
- NINE 32.43
- CVKD 4.79
About NINE Nine Energy Service Inc.
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.